Author(s):
Akash Jakkannavar, Sneha Patil, Mrityunjaya Patil, Shailendra Suryawanshi
Email(s):
shailendrasss80@gmail.com
DOI:
10.52711/2231-5659.2024.00064 
Address:
Akash Jakkannavar1, Sneha Patil1, Mrityunjaya Patil1, Shailendra Suryawanshi2*
1Department of Pharmacognosy, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi, Karnataka.
2Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi, Karnataka.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2024
ABSTRACT:
Pharmacovigilance, which is often connected with monitoring the safety of conventional pharmaceuticals, has expanded to include herbal medications. The usage of herbal medications has significantly increased worldwide due to their increasing popularity, which is fuelled by people's perceptions of their natural origin and perceived safety. Nonetheless, there are a number of hazards associated with the absence of strict regulatory frameworks and uniform quality controls, including as adulteration, contamination, and variation in active ingredients. The evaluation of adverse reactions and the identification of causative linkages are made more difficult by these considerations. This review explores the many approaches used in the pharmacovigilance of herbal products, such as post-marketing research, active surveillance, and spontaneous reporting systems. Examined is the blending of classical knowledge with contemporary pharmacovigilance techniques, emphasizing the value of multidisciplinary approaches and the part played by medical professionals in identifying and disclosing adverse events. The review also addresses the difficulties in gathering and interpreting data because of the complexity of herbal remedies and the impact of cultural and ethnopharmacological variables. In order to improve the safety profile of herbal medicines, the assessment ends by recommending increased international cooperation, the creation of strong regulatory frameworks, and the promotion of public awareness.
Cite this article:
Akash Jakkannavar, Sneha Patil, Mrityunjaya Patil, Shailendra Suryawanshi. Pharmacovigilance for Herbal Medicines. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(4):407-7. doi: 10.52711/2231-5659.2024.00064
Cite(Electronic):
Akash Jakkannavar, Sneha Patil, Mrityunjaya Patil, Shailendra Suryawanshi. Pharmacovigilance for Herbal Medicines. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(4):407-7. doi: 10.52711/2231-5659.2024.00064 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2024-14-4-12
REFERENCES:
1. Kengar MD, Patole KK, Ade AK, Kumbhar SM, Patil CD, Ganjave AR. Introduction to Pharmacovigilance and Monitoring. Asian Journal of Pharmaceutical Research. 2019; 9(2):116-22. doi: 10.5958/2231-5691.2019.00019.4
2. Naik SA. Review on Pharmacovigilance. Asian Journal of Pharmaceutical Research. 2020; 10(2): 123-8. doi: 10.5958/2231-5691.2020.00024.6
3. Meyboom RH, Egberts AC, Gribnau FW, Hekster YA. Pharmacovigilance in perspective. Drug Safety. 1999; 21:429-47.
4. Waller P, Harrison-Woolrych M. An introduction to pharmacovigilance. John Wiley and Sons; 2017- 1.
5. Moore N, Berdaï D, Blin P, Droz C. Pharmacovigilance–The next chapter. Therapies. 2019; 74(6): 557-67. doi.org/10.1016/j.therap.2019.09.004
6. Nikam NR, Vakhariya RR, Magdum CS. Pharmacovigilance: An Overview. Asian Journal of Research in Pharmaceutical Science. 2019; 9(2): 107-11. doi: 10.5958/2231-5659.2019.00016.X
7. Rohilla A, Singh N, Kumar V, Sharma MK, Dahiya A, Kushnoor A. Pharmacovigilance: needs and objectives. Journal of Advanced Pharmacy Education and Research. 2012; 2(4):201-5.
8. Alhat BR. Pharmacovigilance: an overview. Int J Res Pharm Chem. 2011; 1(4): 2231-781.
9. Routledge P. 150 years of pharmacovigilance. The Lancet. 1998 -18; 351(9110): 1200-1. doi.org/10.1016/S0140-6736(98)03148-1
10. Mall SK, Dipa P, Goswami S, Singh P, Singh RP. Pharmacovigilance programme in India (PvPI): History, Current scenario, future aspects and role in COVID 19. doi: 10.52711/2231-5659.2022.00036
11. Shuka SS, Gidwani B, Pandey R, Rao SP, Singh V, Vyas A. Importance of pharmacovigilance in Indian pharmaceutical industry. Asian Journal of Research in Pharmaceutical Science. 2012; 2(1):4-8. doi: 10.52711/2231-5659
12. Mann RD, Andrews EB, editors. Pharmacovigilance. John Wiley and Sons; 2007 - 6.
13. Edwards IR, Olsson S. The WHO international drug monitoring programme. InSide Effects of Drugs Annual. 2003; 26:548-557. Elsevier. doi.org/10.1016/S0378-6080(03)80057-0
14. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Safety. 1998; 19(1): 1-10.
15. Soundalgekar S, Naik A, Hullatti K, Jalalpure S, Patil S, Gaonkar VP. HPTLC fingerprinting and anti-asthmatic activity of roots of two different sources of Bharangi. Indian Journal of Natural Products. 2021; 35(1).
16. Patil S, Khushwah P, Gudasi S, Patil M, Kunchanur M, Koli R. Simultaneous Determination of Gallic Acid, Berberine and Trigonelline in Polyherbal Churna by HPTLC Method. Journal of Young Pharmacists. 2024; 16(2):261-8. doi:10.5530/jyp.2024.16.34
17. Goswami R, Kaushal R, Kumawat D, Ahirwar M. Ensuring Medication Safety in India: The Crucial Role of the Pharmacovigilance Programme of India (PvPI) in Adverse Drug Event Monitoring. Research Journal of Science and Technology. 2024; 16(2):159-2. doi: 10.52711/2349-2988.2024.00023
18. Patton K, Borshoff DC. Adverse drug reactions. Anaesthesia. 2018; 73:76-84. doi.org/10.1111/anae.14143
19. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of adverse drug reactions by nurses. British Journal of Clinical Pharmacology. 1995; 40(2): 173-5. doi.org/10.1111/j.1365-2125.1995.tb05774.
20. Hussin AH. Adverse effects of herbs and drug-herbal interactions. Malaysian Journal of Pharmacy (MJP). 2002-1;1(2):39-44. doi: 10.52494/CGMK2164
21. Chauhan VS. Standardizing herbs and intermediates-newer approaches. The Pharma Review. 2006; 2:37-44. doi: 10.52711/2231-5659.2023.00052
22. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Safety. 2003; 26:829-51. doi: 10.2165/00002018-200326120-00001.
23. Swathi J, Venkatesh DN. A review of herbal regulations in India and Worldwide. Research Journal of Pharmacy and Technology. 2022; 15(3): 1348-52. doi: 10.52711/0974-360X.2022.00225
24. Roden S, Gibbs T. CIOMS Working Groups and their contribution to pharmacovigilance. Pharmacovigilance. 2007: 287-305. doi:10.1002/0470853093.ch25
25. Khattri S, Balamuralidhara V, Pramod KT, Valluru R, Venkatesh MP. Pharmacovigilance regulations in India: A Step forward. Clinical Research and Regulatory Affairs. 2012-1; 29(2): 41-5. doi:10.3109/10601333.2012.692688
26. WHO Expert Committee. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products, the use of essential drugs. Sixth report of the WHO expert committee. Geneva: WHO Technical Report Series. 1995.
27. Zhang J, Wider B, Shang H, Li X, Ernst E. Quality of herbal medicines: challenges and solutions. Complementary therapies in medicine. 2012; 20(1-2): 100-6. doi: 10.1016/j.ctim.2011.09.004.
28. Jacob D, Marrón B, Ehrlich J, Rutherford PA. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug, Healthcare and Patient Safety. 2013; 15: 105-12. doi: 10.2147/DHPS.S43104
29. Härmark L, van Grootheest A. Pharmacovigilance: methods, recent developments and future perspectives. European Journal of Clinical Pharmacology. 2008; 64: 743-52. doi: 10.1007/s00228-008-0475-9.
30. Bigoniya P. Pharmacovigilance of herbal medicines: current status and future strategies. The Pharma Review. 2009; 5:77-88.
31. Härmark L, van Grootheest A. Pharmacovigilance: methods, recent developments and future perspectives. European Journal of Clinical Pharmacology. 2008; 64:743-52. doi: 10.1007/s00228-008-0475-9.
32. Rohilla A, Singh N, Kumar V, Sharma MK, Dahiya A, Kushnoor A. Pharmacovigilance: needs and objectives. Journal of Advanced Pharmacy Education and Research. 2012; 2(4): 201-5.
33. Skalli S, Wang JB, Hugman B. Pharmacovigilance of herbal medicines: The vigilance of tomorrow. Evidence-Based Validation of Herbal Medicine. 2022; 1:239-50. doi.org/10.1016/B978-0-323-85542-6.00001-9
34. Kumar P, Nandave M, Kumar A, Nandave D. Herbovigilance. In Pharmacovigilance Essentials: Advances, Challenges and Global Perspectives 2024;4: 243-267.
35. Fokunang ET, Fonmboh DJ, Mballa RN, Nyuyki AB, Fokunang LB, Kaba N, Abong TB, Duerr R, Richard E, Ondoua MT, Fokunang CN. Pharmacovigilance of natural herbal medicines research for efficacy, safety and quality assurance of phytomedicine products. J. Complement. Altern. Med. Res. 2020: 21-37.
36. Tabach R. Phytopharmacovigilance. Phytotechnology. 2021; 30: 327-346). CRC Press.
37. Ponnusankar S, Venkatesh P, Venkatesh M, Mandal SC, Mukherjee PK. Herbal drugs require pharmacovigilance study-need and reality. The Pharma Review. 2007; 12:113-20.
38. Chakraverty R, Banerjee A. Emerging issues in pharmacovigilance of herbal medicines in India. Int J Pharm Sci Rev Res. 2013; 20:40-2.
39. Rahman SZ, Khan RA, Latif A. Importance of pharmacovigilance in Unani system of medicine. Indian Journal of Pharmacology. 2008; 40(Suppl 1):S17-20.
40. Dal Molim G, de Souza Braga M, Satiko Kikuchi I, R Nemţanu M, Dua K, de Jesus Andreoli Pinto T. The microbial quality aspects and decontamination approaches for the herbal medicinal plants and products: an in-depth review. Current Pharmaceutical Design. 2016; 22(27): 4264-87. doi: 10.2174/1381612822666160623070829
41. Wal A, Wal P, Gupta S, Sharma G, Rai AK. Pharmacovigilance of herbal products in India. Journal of Young Pharmacists. 2011; 3(3): 256-8 doi: 10.4103/0975-1483.83780
42. Kuhn MA. Herbal remedies: drug-herb interactions. Critical Care Nurse. 2002; 22(2): 22-32.
43. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Annals of Pharmacotherapy. 2000; 34(12):1478-82. doi: 10.1345/aph.10031.
44. Choudhury A, Singh PA, Bajwa N, Dash S, Bisht P. Pharmacovigilance of herbal medicines: Concerns and future prospects. Journal of Ethnopharmacology. 2023; 12: 116383. doi: 10.1016/j.jep.2023.116383.
45. Manoj S, Raman S, Gupta VB, Chatterjee A. Pharmacovigilance of herbal medicines. The Pharma Review. 2006; 12:119-24.
46. Matole V, Thorat Y, Ghurghure S, Ingle S, Birajdar A, Nangare G, Safwan M, Madur S, Patil S, Bagalkote Z, Sakhare A. A brief review on herbal medicines. Research Journal of Pharmacognosy and Phytochemistry. 2021; 13(2): 101-2. doi: 10.52711/0975-4385.2021.00016
47. Mariyam N, Ezhilarasan D. Pharmacovigilance of the herbal medicines use: A review on case reports. J. Afr. 2016; 3: 294-303.
48. Ragul VV, Saranya P. Pharmacovigilance-an overview in a pharmacist perspective. Research Journal of Pharmacy and Technology. 2020; 13(8): 3941-6. doi: 10.5958/0974-360X.2020.00697.6
49. Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized Gingko biloba use after liver transplantation. Transplant International. 2002; 15: 377-9. doi: 10.1007/s00147-002-0432-y.
50. Fokunang ET, Fonmboh DJ, Mballa RN, Nyuyki AB, Fokunang LB, Kaba N, Abong TB, Duerr R, Richard E, Ondoua MT, Fokunang CN. Pharmacovigilance of natural herbal medicines research for efficacy, safety and quality assurance of phytomedicine products. J. Complement. Altern. Med. Res. 2020: 21-37.
51. Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Brazilian Journal of Medical and Biological Research. 2000; 33: 179-89. doi: 10.1590/s0100-879x2000000200004.
52. Yau WP, Goh CH, Koh HL. Quality control and quality assurance of phytomedicines: Key considerations, methods, and analytical challenges. Phytotherapies: Efficacy, Safety, and Regulation. 2015; 24: 18-48. doi:10.1002/9781119006039.ch2
53. Maqbool M, Dar MA, Rasool S, Bhat AU, Geer MI. Drug safety and Pharmacovigilance: An overview. Journal of Drug Delivery and Therapeutics. 2019; 15; 9(2-s): 543-8. doi:doi.org/10.22270/jddt.v9i2-s.2469
54. Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. Journal of Young Pharmacists. 2010; 2(3): 315-20 doi: 10.4103/0975-1483.66802
55. Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. British Journal of Clinical Pharmacology. 1988; 26(1): 1. doi: 10.1111/j.1365-2125.1988.tb03356.x
56. Létinier L, Ferreira A, Marceron A, Babin M, Micallef J, Miremont-Salamé G, Pariente A, French Network of Pharmacovigilance Centres. Spontaneous Reports of Serious Adverse Drug Reactions Resulting from Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database. Frontiers in Pharmacology. 2021; 24(11): 624562.
57. Hassan MA. Need to incorporate pharmacovigilance of herbal medicine to the curriculum. National Journal of Physiology, Pharmacy and Pharmacology. 2014; 4(2): 99 doi: 10.5455/njppp.2014.4.080620141
58. Skalli S, Bencheikh RS. Safety monitoring of herb-drug interactions: a component of pharmacovigilance. Drug Safety. 2012; 35: 785-91.
59. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology. 2014; 10(4): 66193. doi.org/10.3389/fphar.2013.00177
60. Hassan MA. Need to incorporate pharmacovigilance of herbal medicine to the curriculum. National Journal of Physiology, Pharmacy and Pharmacology. 2014-1; 4(2):99. doi: 10.5455/njppp.2014.4.080620141
61. Pai V, Subraya CK, Holavana Halli Nanjundaiah AR, Kamath V, Kunhikatta V. Issues and challenges in pharmacovigilance of Herbal formulations. Current Drug Safety. 2024 Feb 1; 19(1): 19-23.
62. Skalli S, Bencheikh RS. Pharmacovigilance of herbal medicines in Africa: Questionnaire study. Journal of Ethnopharmacology. 2015; 2(171): 99-108.doi.org/10.1016/j.jep.2015.05.033
63. Saad B, Azaizeh H, Abu-Hijleh G, Said O. Safety of traditional Arab herbal medicine. Evidence-Based Complementary and Alternative Medicine. 2006;1(3):4339 doi.org/10.1093/ecam/nel058.
64. Londhe VP, Chanshetti R, Dhole SN. Past, Present and Future. Asian Journal of Pharmaceutical Research. 2024 Jun 1; 14(2). doi: 10.52711/2231-5691.2024.00029
65. Bhimaneni S, Sharma R, Dey P, Kumar A. Pharmacovigilance of herbal medicines: an overview. Evidence Based Validation of Traditional Medicines: A comprehensive Approach. 2021: 513-35.
66. Kurhekar JV. Ancient and modern practices in phytomedicine. In Preparation of Phytopharmaceuticals for the Management of Disorders 2021;1: 55-75. Academic Press. doi.org/10.1016/B978-0-12-820284-5.00019-8.
67. Srinivas M, Santhosh J, Swetha K. The Present and Future Prospectives of Pharmacovigilance. International Journal of Pharmaceutical Sciences Review and Research. 2023: 85-91. doi: 10.47583/ijpsrr.2023.v78i02.013.
68. Sunil J, Bhaskar K, Shailendra S. Quality Control and Standardization of Phytomedicines. Nirali Prakashan. 2022: 1.1-18.10.